Endoskopie, 2011; 20(3-4): 96-99
Endoscopic treatment of neurogenic detrusor overactivity - submucosal application of botulinum A toxin
- Urologické oddělení, Krajská nemocnice Liberec, a.s.
Treatment of neurogenic detrusor overactivity using botulinum A toxin is the first option for patients refractory to anticholinergic drugs.
This study is aimed on new way of administration – submucosal application.
Material and Methods: 10 patients with neurogenic detrusor overactivity after spinal cord injury in age between 19 and 39 years. Treatment
was performed by cystoscopic application 300 U of Botox®. The drug was administered submucosaly. Evaluation of urodynamic
parameters and voiding diary were done before and 12 weeks after treatment.
Results: Three months after treatment maximal cystometric capacity increased from 212.2±84.2 ml to 442.5±81.7 ml (p<0.05). Maximal
detrusor pressure during involuntary contraction decreased from 84.2±25.3 cmH2O to 53.1±18.4 cmH2O (p<0.05). Number of incontinence
episodes decreased from 13.8±5.1 na 3.2±0.9 (p<0.05). Continence rate was 90 %.
Conclusion: Submucosal application of botulinum A toxin in period 3 month after treatment improved all monitored urodynamic parametres
and reduced numbers of episodes of incontinence.
Keywords: botulinum toxin, detrusor overactivity, incontinence, submucosal application
Published: December 28, 2011 Show citation
References
- Dykstra D, Sidi A, Scott A, et al. Effects of botulinum-A toxin on detrusor sphincter dyssynergia in spinal cord injury patients. J Urol 1988; 139: 919-922.
Go to original source... 
Go to PubMed... - Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Uro 2003; 44: 165-174. Go to original source... Go to PubMed...
- Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312: 692-596. Go to original source... Go to PubMed...
- Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford A, Davis J, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibres following intradetrusor injections of botulinum toxin for human detrusor overactivity. JUrol 2005: 174: 977-983. Go to original source...
- Giannantoni A, Di Stasi S, Nadricchi V, Zuchi A, Machcioni L, Bini V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006; 175: 2341-2344. Go to original source... Go to PubMed...
- Haferkapm A, Schurch B, Reitz A, Krengel U, Grosse J, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neuorogenic bladder. Eur Urol 2004; 46: 784-791. Go to original source... Go to PubMed...
- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A. Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61(1): 37-49. Go to original source... Go to PubMed...
- Mehnert U, Boy S, Schmid M, Reitz A, von Hessling A, Hodler J, et al. A morphological evaluation of botulinum neurotoxin A injections into detrusor muscle using magnetic resonance imaging. J Urol 2009; 27: 397-409. Go to original source... Go to PubMed...
- Patel A, Patterson J, Chapple C. Botulinum Toxin injections for neuorogenic and idiopathic detrusor overactivity: A critical analysis of results. Eur Urol 2006; 50: 684-710. Go to original source... Go to PubMed...
- Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox(R)) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2008; 53: 275-87. Go to original source... Go to PubMed...
- Meguid TA. Botulinumtoxin-A injections into neurogenic overactive bladder - to include or exclude the trigone? A prospective randomized, controlled trial. J Urol 2010; 184: 2423-2428. Go to original source... Go to PubMed...
- Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injection of botulinum toxin A for idiopathic detrusor overactivity. J Urol 2007; 178: 1359-1363. Go to original source... Go to PubMed...
- Giannantoni A, Mearini E, Del Zengrano M, Perena M. Six year follow-up of botulinum toxin A intradetrusorial injection in patient with refractory neurogenic detrusor overactivity: clinical and urodynamic results. EurUrol. In press; doi: 10.1016/j.eururo.2008.08.048.
- Truzzi JC, Bruschini H, Simoneti R, Miguel S. What is the best dose for intravesical botulinum A toxin injection in overactive bladder treatment? A prospective randomised preliminary study. Join meeting of the International Continence Society (ICS) ant the International Uro-Gynecological association (IUGA), Paris, France, Aug 25-27, 2004.
- Gausse A, Tunuguntla HS, Rodroiguez G, Velzazquez D. Dose finding prospective randomized study to evaluace the efficacy and safety of botulinum A toxin for refractory idiopathic overactive bladder Interanational Continence Society Annual Meeting, Montreal, Canada, Aug 2005: Abstract 254.
- Reitz J, Schurch B. Botulinum toxin type B injection for management of type A resistant neuorogenic detrusor overactivity. J Urol 2004; 171: 804-805. Go to original source... Go to PubMed...
- Krhut J, Zachoval R, Hradílek O, Zapletalová O. Botulotoxin v léčbě detruzorové hyperaktivity u pacientek s roztrouąenou sklerózou. Cesk Slov neurol N 2008; 71/104(4): 429-434.
- Krhut J, ©ámal V, Němec D. Porovnání efektivity intradetruzorové a subslizniční injekce botulinumtoxinu A u pacientů s neurogenní hyperaktivitou detruzoru. Ces Urol 2011; 15(Suppl. 2): 75 (abstrakt 107).
- Sampaio C, Costa J, Fereira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004; 19(Suppl. 8): 129-136. Go to original source... Go to PubMed...